Product Description: Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive MEK inhibitor[1][2][3].
Formula: C16H14F3IN2O4
References: [1]Avolio E, et al. Cardiac pericyte reprogramming by MEK inhibition promotes arteriologenesis and angiogenesis of the ischemic heart. J Clin Invest. 2022 May 16;132(10):e152308./[2]Suo N, et al. Inhibition of MAPK/ERK pathway promotes oligodendrocytes generation and recovery of demyelinating diseases. Glia. 2019 Jul;67(7):1320-1332./[3]Ai Z, et al. Maintenance of Self-Renewal and Pluripotency in J1 Mouse Embryonic Stem Cells through Regulating Transcription Factor and MicroRNA Expression Induced by PD0325901. Stem Cells Int. 2016;2016:1792573.
CAS Number: 391210-10-9
Molecular Weight: 482.19
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: MEK
English
Deutsch
